TY - JOUR
T1 - RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan
AU - Kameyama, Kaori
AU - Okinaga, Hiroko
AU - Takami, Hiroshi
PY - 2004/6
Y1 - 2004/6
N2 - The familial form of medullary thyroid carcinoma (MTC) is caused by mutations of the RET protooncogene. We registered 60 multiple endocrine neoplasia (MEN) 2A patients, 12 familial non-MEN medullary carcinoma (FMTC) patients, and three MEN2B patients with a confirmed RET germline mutation. All 60 MEN2A patients had RET mutations in a cysteine-rich domain. Seven of the FMTC patients had a mutation in cysteine-rich domain, and the other five had a mutation in codon 768, which encodes a tyrosine-kinase domain. Two of the MEN2B patients had a mutation in codon 918, and one patient had a double mutation, one in codon 804 and the other in codon 806, both of which are all encoded tyrosine-kinase domain. The genotype-phenotype correlations of our data will allow individualized recommendations for the optimal timing of prophylactic surgery.
AB - The familial form of medullary thyroid carcinoma (MTC) is caused by mutations of the RET protooncogene. We registered 60 multiple endocrine neoplasia (MEN) 2A patients, 12 familial non-MEN medullary carcinoma (FMTC) patients, and three MEN2B patients with a confirmed RET germline mutation. All 60 MEN2A patients had RET mutations in a cysteine-rich domain. Seven of the FMTC patients had a mutation in cysteine-rich domain, and the other five had a mutation in codon 768, which encodes a tyrosine-kinase domain. Two of the MEN2B patients had a mutation in codon 918, and one patient had a double mutation, one in codon 804 and the other in codon 806, both of which are all encoded tyrosine-kinase domain. The genotype-phenotype correlations of our data will allow individualized recommendations for the optimal timing of prophylactic surgery.
KW - Familial cancer
KW - Medullary thyroid carcinoma
KW - RET protooncogene
UR - http://www.scopus.com/inward/record.url?scp=3242665308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3242665308&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2004.05.001
DO - 10.1016/j.biopha.2004.05.001
M3 - Article
C2 - 15271413
AN - SCOPUS:3242665308
SN - 0753-3322
VL - 58
SP - 345
EP - 347
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
IS - 6-7
ER -